grant

Role of GLIS3 in Human Pancreatic Beta Cell Generation, Survival and Proliferation

Organization WEILL MEDICAL COLL OF CORNELL UNIVLocation NEW YORK, UNITED STATESPosted 1 Jan 2024Deadline 31 Dec 2027
NIHUS FederalResearch GrantFY2025ATAC sequencingATAC-seqATACseqAdult-Onset Diabetes MellitusAffectAllelesAllelomorphsApoptosisApoptosis PathwayAssay for Transposase-Accessible Chromatin using sequencingB7 family member, H4B7 superfamily member 1B7-H4B7H4B7S1B7XBeta CellBindingBiological FunctionBiological ProcessBone-Derived Transforming Growth FactorBrittle Diabetes MellitusCell BodyCell Communication and SignalingCell DeathCell DifferentiationCell Differentiation processCell FunctionCell Growth in NumberCell MultiplicationCell PhysiologyCell ProcessCell ProliferationCell SignalingCell SurvivalCell ViabilityCellsCellular FunctionCellular PhysiologyCellular ProcessCellular ProliferationCellular StressCellular Stress ResponseCellular biologyD CellsD-GlucoseDNA mutationDeath RateDelta CellDextroseDiabetes MellitusDiabetes mellitus syndrome in newborn infantDiseaseDisorderDrugsEndocrineEnvironmental FactorEnvironmental Risk FactorFLJ22418Fatty AcidsGWA studyGWASGene variantGenerationsGenesGeneticGenetic ChangeGenetic defectGenetic mutationGlucoseGoalsHumanHumulin RIDDMImpairmentIn VitroInsulinInsulin CellInsulin Secreting CellInsulin-Dependent Diabetes MellitusIntracellular Communication and SignalingJV18JV18-1Juvenile-Onset Diabetes MellitusKetosis-Prone Diabetes MellitusKetosis-Resistant Diabetes MellitusKnock-outKnockoutKnowledgeLigandsMADH2MADH2 geneMADR2Maturity-Onset Diabetes MellitusMedicationMiceMice MammalsMilk Growth FactorModern ManMolecularMolecular InteractionMurineMusMutationNIDDMNatureNon-Insulin Dependent DiabetesNon-Insulin-Dependent Diabetes MellitusNoninsulin Dependent DiabetesNoninsulin Dependent Diabetes MellitusNovolin ROutcomePancreasPancreaticPancreatic beta CellPancreatic β-CellPathway interactionsPatientsPharmaceutical PreparationsPlatelet Transforming Growth FactorPopulationPrecision therapeuticsProgrammed Cell DeathProliferatingProteinsRNA SeqRNA sequencingRNAseqRegular InsulinReportingResearch ResourcesResourcesRiskRoleSMAD2Signal TransductionSignal Transduction SystemsSignalingSingle Base PolymorphismSingle Nucleotide PolymorphismSlow-Onset Diabetes MellitusSomatostatin CellsSomatostatin Secreting CellStable Diabetes MellitusStructure of beta Cell of isletSubcellular ProcessSudden-Onset Diabetes MellitusSystemT1 DMT1 diabetesT1DT1DMT2 DMT2DT2DMTGF BTGF-betaTGF-βTGFbetaTGFβTestingTransforming Growth Factor betaTransforming Growth Factor-Beta Family GeneType 1 Diabetes MellitusType 1 diabetesType 2 Diabetes MellitusType 2 diabetesType I Diabetes MellitusType II Diabetes MellitusType II diabetesV-set domain containing T cell activation inhibitor 1VTCN1VTCN1 geneVariantVariationZinc Finger DomainZinc Finger MotifsZinc Fingersadult onset diabetesallelic variantassay for transposase accessible chromatin followed by sequencingassay for transposase accessible chromatin seqassay for transposase accessible chromatin sequencingassay for transposase-accessible chromatin with sequencingbeta cell developmentbiological signal transductioncell biologycell stresscell typecellular differentiationdevelop therapydiabetesdiabetes mellitus therapydiabetes therapydrug developmentdrug/agentendocrine pancreas developmentenvironmental riskgene functiongenetic variantgenome mutationgenome wide associationgenome wide association scangenome wide association studygenomewide association scangenomewide association studygenomic varianthESChuman ES cellhuman ES cell lineshuman ESChuman diseasehuman embryonic stem cellhuman embryonic stem cell linehuman modelhumanized micehumanized mouseimprovedin vivoinhibitorinnovateinnovationinnovativeinsulin dependent diabetesinsulin dependent type 1intervention developmentisletislet developmentjuvenile diabetesjuvenile diabetes mellitusketosis prone diabetesketosis resistant diabetesknockout genematurity onset diabetesmembermodel of humanmortality ratemortality ratiomouse developmentmouse modelmurine modelnecrocytosisneonatal diabetesneonatal diabetes mellitusnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetoverexpressoverexpressionpancreas beta cellpancreas developmentpancreas β cellpancreatic b-cellpathwayprecision therapiesprecision treatmentpromoterpromotorscRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle nucleotide variantsingle-cell RNA sequencingsocial roletheoriestherapy developmenttranscriptome sequencingtranscriptomic sequencingtreatment developmenttype 1 and type 2 diabetestype 2 DMtype I and type II diabetestype I diabetestype II DMtype one diabetestype two diabeteswhole genome association analysiswhole genome association studyβ-cellβ-cellsβCell
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Abstract.
Genome-wide association studies have identified numerous genetic variants associated with type 1 and type 2

diabetes mellitus (T1DM and T2DM), many of which might affect genes that are involved in pancreatic β cell

function and survival. However, the exact biological functions and the mechanistic nature of these genetic

variants remain unclear. Human embryonic stem cells (hESCs), provide, in theory, unlimited resources to

generate differentiated cells to study the role of genetic factors in human diseases. Of the diabetes-associated

genes identified so far, GLIS3 is the only one (other than insulin) associated with both T1DM and T2DM, and

neonatal diabetes mellitus (NDM). Recently, we reported an optimized strategy to efficiently derive GLIS3+

pancreatic β-like cells. Using this platform, we found that loss of GLIS3 causes impaired differentiation toward β

cells and increases β cell death.

Here, we propose to test the hypothesis that genetic and environmental factors caused loss or reduction of

GLIS3 impairs human pancreatic β cell generation, survival, and proliferation in both healthy and disease

conditions. In preliminary studies, we have created 2 isogenic T2DM-SNP-hESCs, 2 isogenic NDM-M-hESCs,

and 2 isogenic KO (knockout)-hESC lines. In addition, we identified a TGFβ inhibitor that rescues the increased

death rate in GLIS3-/- β-like cells. In this proposal, we will systematically study the differentiation of isogenic

T2DM-SNP-hESCs, NDM-M-hESCs, and GLIS3-KO-hESCs, exploring the generation, function, and survival of

the endocrine cells in the disease conditions. Additionally, we will explore the downstream mechanism of GLIS3.

Finally, we will develop approaches to improve β cell survival in T2DM conditions by targeting GLIS3 and its

downstream pathways. Toward these goals, the following aims are proposed: Aim 1. Evaluate the impact of

GLIS3-associated genetic variants in the generation and survival of human pancreatic β cells both in vitro and

in vivo. Aim 2. Decode the molecular mechanism of GLIS3 controlling human pancreatic β cell survival. Aim 3.

Rescue T2DM islets survival by targeting GLIS3 and its downstream mechanisms.

This proposal will systematically analyze the biological function of GLIS3 and associated variants in human β

cell's generation, survival, and proliferation. It will significantly enhance our knowledge of β cell biology, which

will pave the road for developing novel therapies for T2DM patients.

Grant Number: 5R01DK136005-02
NIH Institute/Center: NIH

Principal Investigator: Shuibing Chen

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →